Press Releases

SEC Filing Details

Document Details

Form
4
Filing Date
Jul 11, 2022
Document Date
Jul 11, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Entasis Therapeutics Holdings Inc.
Issuer
ENTASIS THERAPEUTICS HOLDINGS INC.
Filer
Altarac David

"Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections."

— Ruben Tommasi, Chief Scientific Officer